Clinical Trial Update: Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating olaparib with or without durvalumab for biliary tract cancer with DNA damage repair mutations after platinum chemotherapy; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Asan Medical Center | Conditions: Biliary Tract Cancer, DNA Damage Repair Deficiency | Phase 2 | Status: RECRUITING